Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $848000.0.

  • Artiva Biotherapeutics' Accounts Payables fell 3020.58% to $848000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $848000.0, marking a year-over-year decrease of 3020.58%. This contributed to the annual value of $1.1 million for FY2024, which is 8257.33% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Accounts Payables stood at $848000.0 for Q3 2025, which was down 3020.58% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Accounts Payables registered a high of $2.0 million during Q1 2025, and its lowest value of $614000.0 during Q4 2023.
  • For the 3-year period, Artiva Biotherapeutics' Accounts Payables averaged around $1.1 million, with its median value being $1.1 million (2024).
  • As far as peak fluctuations go, Artiva Biotherapeutics' Accounts Payables surged by 8257.33% in 2024, and later tumbled by 3020.58% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Accounts Payables stood at $614000.0 in 2023, then soared by 82.57% to $1.1 million in 2024, then fell by 24.35% to $848000.0 in 2025.
  • Its Accounts Payables was $848000.0 in Q3 2025, compared to $1.2 million in Q2 2025 and $2.0 million in Q1 2025.